Inclusive Innovation at Mass General Brigham Custom Case Solution & Analysis

1. Evidence Brief: Case Data Extraction

Financial Metrics

• Annual Research Budget: Approximately 2.3 billion dollars in annual research funding, making it the largest hospital-based research enterprise in the United States. Source: Case Introduction.
• System Revenue: Total annual operating revenue exceeds 14 billion dollars. Source: Financial Overview section.
• United Against Racism (UAR) Investment: Initial multi-million dollar commitment to address systemic racism and health inequities. Source: UAR Program Description.
• Clinical Trial Costs: High overhead associated with traditional clinical trials, often exceeding 20,000 dollars per participant in specialized therapeutic areas. Source: Exhibit on Research Operations.

Operational Facts

• Institutional Scale: 14 member institutions including Massachusetts General Hospital and Brigham and Womens Hospital. Source: Organizational Structure.
• Workforce: Approximately 80,000 employees including 6,500 physicians and 9,000 researchers. Source: Personnel Data.
• Patient Reach: Over 1.5 million patients served annually across the Massachusetts region. Source: Patient Statistics.
• Research Infrastructure: Over 1 million square feet of dedicated research space. Source: Facility Records.
• Digital Health: Rapid expansion of telehealth services during the COVID-19 pandemic, reaching a peak of 12,000 visits per day. Source: Digital Health Transition section.

Stakeholder Positions

• Anne Klibanski (CEO): Asserts that health equity is a fundamental component of the organization’s clinical and research mission. Demands integration of equity into the core business model. Source: CEO Strategy Memo.
• Ravi Thadhani (Chief Academic Officer): Focuses on diversifying the research workforce and clinical trial participants. Argues that inclusive innovation improves the quality of science. Source: Research Leadership Briefing.
• Elsie Taveras (Chief Community Health Equity Officer): Advocates for community-based participatory research and addressing social determinants of health directly through clinical interventions. Source: Community Health Strategy.
• Academic Researchers: Express concerns regarding the speed of implementation and the potential for increased administrative burden in securing grants. Source: Faculty Survey Results.

Information Gaps

• Specific Diversity Data: The case lacks a granular breakdown of current clinical trial participation by ethnicity across all 14 institutions.
• Long-term Funding: No detailed 10-year financial plan for sustaining the United Against Racism initiative beyond the initial commitment.
• Competitor Benchmarking: Limited data on how peer academic medical centers (e.g., Mayo Clinic, Johns Hopkins) are funding similar inclusive innovation programs.

2. Strategic Analysis

Core Strategic Question

How can Mass General Brigham (MGB) transition from a traditional academic research model to an inclusive innovation framework without compromising its global leadership in high-acuity medical breakthroughs?

Structural Analysis: Value Chain Lens

The current MGB research value chain is optimized for high-end discovery but suffers from significant friction in the distribution and inclusivity phases. Findings include:

• Inbound Research: Heavily weighted toward NIH funding which historically rewards established researchers, creating a barrier for diverse talent.
• Operations (Clinical Trials): Recruitment protocols are centered on hospital campuses, effectively excluding populations with transportation or childcare constraints.
• Outbound Distribution: Breakthroughs often reach affluent patient segments first, creating a lag in health outcomes for marginalized communities.

Strategic Options

Preliminary Recommendation

MGB should pursue Structural KPI Integration as the primary path. While decentralized hubs and venture funds are valuable, they remain peripheral unless the core incentive structure of the organization changes. By making equity a non-negotiable metric for departmental success, MGB forces the integration of inclusive practices into the existing 2.3 billion dollar research engine.

3. Operations and Implementation Roadmap

Critical Path

The transition to inclusive innovation requires a sequenced 18-month rollout focused on institutionalizing equity within the research lifecycle.

• Phase 1 (Months 1-6): Data Infrastructure. Standardize race, ethnicity, and language (REAL) data collection across all 14 institutions. Establish a baseline for current trial diversity.
• Phase 2 (Months 7-12): IRB and Grant Reform. Modify Institutional Review Board (IRB) protocols to require a diversity recruitment plan for all new human subject studies.
• Phase 3 (Months 13-18): Performance Alignment. Link 15 percent of departmental leadership bonuses to the achievement of equity-in-research targets.

Key Constraints

• Academic Inertia: The tenure and promotion system currently rewards publication volume and grant dollars over community impact. Overcoming this requires a fundamental shift in faculty bylaws.
• Data Silos: Legacy IT systems across the 14 member hospitals do not communicate seamlessly, making real-time tracking of diversity metrics difficult.

Risk-Adjusted Implementation Strategy

To mitigate the risk of researcher alienation, MGB will implement a tiered incentive model. Instead of immediate penalties for non-compliance, the first 12 months will focus on providing concierge support for diversity recruitment. This includes a centralized pool of bilingual research coordinators and community liaisons funded by the central office. This reduces the operational friction for researchers while maintaining the mandate for inclusivity. Contingency planning includes a 10 percent budget reserve to address unforeseen regulatory hurdles in community-based trial sites.

4. Executive Review and BLUF

BLUF (Bottom Line Up Front)

Mass General Brigham must institutionalize inclusive innovation as a core operational requirement rather than a peripheral social initiative. To maintain its status as a premier research institution, MGB must bridge the gap between elite discovery and equitable delivery. The strategy requires three immediate actions: standardizing equity data across all 14 institutions, mandating diversity recruitment plans for all internal funding, and linking executive compensation to these outcomes. Failure to act will result in diminishing clinical relevance and potential loss of federal funding as NIH requirements for trial diversity tighten. The organization must pivot from a holding company of independent hospitals to a unified system where equity is a primary measure of scientific excellence.

Dangerous Assumption

The single most consequential unchallenged premise is that federal and private payers will eventually reimburse the higher costs associated with inclusive research and community-based care. If reimbursement models remain tied to traditional volume-based metrics, the financial burden of these equity initiatives could become unsustainable for the operating margin.

Unaddressed Risks

• Regulatory Compliance: Shifting clinical trials to community settings increases the risk of protocol deviations and data integrity challenges that could jeopardize FDA approvals.
• Brand Dilution: There is a risk that focusing heavily on community health could be perceived by donors and top-tier talent as a pivot away from high-acuity, cutting-edge medical science.

Unconsidered Alternative

The analysis focused on internal reform, but MGB could consider a Platform Orchestration model. Instead of conducting all inclusive research internally, MGB could act as a certification body and data aggregator for a broader network of smaller, community-based hospitals. This would expand the patient pool for trials by 5x without the capital intensity of building new facilities or modifying internal academic structures.

Verdict

APPROVED FOR LEADERSHIP REVIEW